At Circio we recognize the scientific and commercial value of collaborating with academic and industry partners.

Strategic focus areas

Circio is developing circular RNA expression technology for safer and better gene and cell therapies. Circio is considered the global leader in vector-delivered circRNA therapeutics, with lead programs for AAV gene therapy and in vivo CAR-T cell therapy. The Group is focused on accelerating the development of the proprietary circVec platform to capitalize on its significant early-mover advantage in the expanding fields of gene and cell therapy.

The Group’s strategy is to:

• Establish circVec as a versatile platform technology for therapeutic candidates in areas of high unmet medical need
• Establish technology partnerships which broaden and/or enhance the potential applications of circVec
• Enter licensing or collaboration partnerships to expand the development scope, create multiple shots on goal and monetize the circVec platform

Circio´s business development aims are three-fold:

i) Capitalize on the platform to bring non-dilutive funding into the company to support in house development programs

ii) Identify and test complementary technologies that can further enhance and expand the applications of the platform

iii) Broaden the development scope in order to generate more validating data and spread R&D risk